The continuing role of prostate-specific antigen as a marker for localized prostate cancer: 'Do not throw the baby out with the bath water'

BJU International

Volumn 104, Issue 11, 2009, Pages 1553-1554

  Challacombe, Ben J ^a   Murphy, Declan ^a   Lilja, Hans ^b,c   Vickers, Andrew J ^c   Costello, Anthony J ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b LUND UNIVERSITY   (Sweden)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

AGE DISTRIBUTION; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; FOLLOW UP; HUMAN; NOTE; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

ADULT; AGE FACTORS; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 70449331626     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08881.x     Document Type: Note

References (14)

1. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987 317 : 909 916
2. Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991 324 : 1156 1161
3. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003 349 : 215 224
4. Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In Walsh PC, Retik AB, Vaughan ED Jr., Wein AJ, Campbell's Urology, 8th edn. Philadelphia : W.B. Saunders Co., 2002 : 1297 1336
5. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999 53 : 581 589
6. Hammerer PG, McNeal JE, Stamey TA. Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate. J Urol 1995 153 : 111 4
7. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004 172 : 1297 1301
8. Lilja H, Ulmert D, Björk T et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44-50 years. J Clin Oncol 2007 25 : 431 436
9. Ulmert D, Cronin AM, Björk T et al. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med 2008 6 : 6
10. Ulmert D, Serio AM, O'Brien MF et al. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 2008 26 : 835 841
11. American Urological Association. Prostate-Specific Antigen Best Practice Statement: 2009 Update. Available at: http://www.auanet.org. Accessed August 2009
12. Andriole GL, Crawford ED, Grubb RL III et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009 360 : 1310 1319
13. Schröder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009 360 : 1320 1328
14. Holmberg L. Prostate cancer screening: the need for problem-solving that puts men's interests first. Eur Urol 2009 Epub ahead of print]. DOI:10.1016/j.eururo.2009.04.026